Global Big Pharma Partnering Terms and Agreements 2014-2020

$3,495.00

Provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals

Publication date
September 2020
Number of pages
1400+
Product type
Research report
Available formats
PDF document
Report edition
3
SKU
CP1010

Global Big Pharma Partnering Terms and Agreements 2014 to 2020 report provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

 

This report provides details of the latest Big Pharma agreements announced in the life sciences since 2014.

 

The report takes the reader through a comprehensive review Big Pharma deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Big Pharma partnering deals.

 

The report presents financial deal term values for Big Pharma deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

 

The middle section of the report explores the leading dealmakers in the Big Pharma partnering field; both the leading deal values and most active Big Pharma dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

 

One of the key highlights of the report is that over 3,100 online deal records of actual Big Pharma deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

 

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

 

The initial chapters of this report provide an orientation of Big Pharma dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Big Pharma dealmaking since 2014, including details of headline, upfront, milestone and royalty terms.

 

Chapter 3 provides a review of the leading Big Pharma deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 50 most active companies including Pfizer, Sanofi, Abbott, GlaxoSmithKline, Johnson & Johnson and many others, in Big Pharma dealmaking with a brief summary followed by a comprehensive listing of Big Pharma deals announded by that company, as well as contract documents, where available.

 

Chapter 5 provides a comprehensive and detailed review of Big Pharma partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive and detailed review of Big Pharma partnering deals signed and announced since Jan 2014. The chapter is organized by specific technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

 

A comprehensive series of appendices is provided organized by Big Pharma partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in Big Pharma partnering and dealmaking since 2014.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Big Pharma technologies and products.

 

Key benefits

 

Global Big Pharma Partnering Terms and Agreements 2014 to 2020 provides the reader with the following key benefits:

 

  • In-depth understanding of Big Pharma deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Big Pharma agreements with real life case studies
  • Detailed access to actual Big Pharma contracts entered into by leading biopharma companies
  • Identify most active Big Pharma dealmakers since 2014
  • Insight into terms included in a Big Pharma partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

 

Report scope

 

Global Big Pharma Partnering Terms and Agreements 2014 to 2020 is intended to provide the reader with an in-depth understanding and access to Big Pharma trends and structure of deals entered into by leading companies worldwide.

 

Big Pharma Partnering Terms and Agreements includes:

       

  • Trends in Big Pharma dealmaking in the biopharma industry since 2014
  • Analysis of Big Pharma deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Big Pharma deals
  • Access to Big Pharma contract documents
  • Leading Big Pharma deals by value since 2014
  • Most active Big Pharma dealmakers since 2014

 

In Global Big Pharma Partnering Terms and Agreements 2014 to 2020, the available deals are listed by:

 

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The Global Big Pharma Partnering Terms and Agreements 2014 to 2020 report provides comprehensive access to available deals and contract documents for over 3,100 Big Pharma deals.

 

Analyzing actual contract agreements allows assessment of the following:

 

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Big Pharma Partnering Terms and Agreements 2014 to 2020 provides the reader with the following key benefits:

 

  • In-depth understanding of Big Pharma deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Big Pharma agreements with real life case studies
  • Detailed access to actual Big Pharma contracts entered into by leading biopharma companies
  • Identify most active Big Pharma dealmakers since 2014
  • Insight into terms included in a Big Pharma partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in Big Pharma dealmaking

 

2.1. Introduction

2.2. Big Pharma partnering over the years

2.3. Most active Big Pharma dealmakers

2.4. Big Pharma partnering by deal type

2.5. Big Pharma partnering by therapy area

2.6. Big Pharma partnering by technology type

2.7. Deal terms for Big Pharma partnering

2.7.1 Big Pharma partnering headline values

2.7.2 Big Pharma deal upfront payments

2.7.3 Big Pharma deal milestone payments

2.7.4 Big Pharma royalty rates

 

Chapter 3 – Leading Big Pharma deals

 

3.1. Introduction

3.2. Top Big Pharma deals by value

 

Chapter 4 – Most active Big Pharma dealmakers

 

4.1. Introduction

4.2. Most active Big Pharma dealmakers

4.3. Most active Big Pharma partnering company profiles

Including Pfizer, Sanofi, Abbott, GlaxoSmithKline, Johnson & Johnson and many others

 

Chapter 5 – Big Pharma contracts dealmaking directory

 

5.1. Introduction

5.2. Big Pharma contracts dealmaking directory

 

Chapter 6 – Big Pharma dealmaking by technology type

 

Chapter 7 – Partnering resource center

 

7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking

 

Appendices

 

Appendix 1 – Big Pharma deals by company A-Z

Appendix 2 – Big Pharma deals by stage of development

Appendix 3 – Big Pharma deals by deal type

Appendix 4 – Big Pharma deals by therapy area

Appendix 5 – Deal type definitions

 

About Wildwood Ventures

 

Current Partnering

Current Agreements

Recent report titles from Current Partnering

 

Table of figures

 

Figure 1: Big Pharma partnering since 2014
Figure 2: Active Big Pharma dealmaking activity– 2014 to 2020
Figure 3: Big Pharma partnering by deal type since 2014
Figure 4: Big Pharma partnering by disease type since 2014
Figure 5: Big Pharma partnering by technology type since 2014
Figure 6: Big Pharma deals with a headline value
Figure 7: Big Pharma deals with an upfront value
Figure 8: Big Pharma deals with a milestone value
Figure 9: Big Pharma deals with a royalty rate value
Figure 10: Top Big Pharma deals by value since 2014
Figure 11: Most active Big Pharma dealmakers 2014 to 2020

Pricing options

  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

1QBit, 3B Pharmaceuticals, 3M Drug Delivery Systems, 3SBio, 4D Molecular Therapeutics, 4D Pharma, 4SC, 23andMe, A*STAR Agency for Science, Technology and Research, A*STAR Singapore Immunology Network, AADi, Aarhus University Hospital, Aastrom Biosciences, AB-Biotics, Abarca, AB Biosciences, Abbott Laboratories, Abbott Vascular Devices, Abbvie, Abcam, AbCellera, Ab E Discovery, Abic Marketing, Abide Therapeutics, Abilita Bio, Abingworth Management, Ab Initio, Abionic, Ablexis, Ablynx, AbMed, Abpro, Abramson Cancer Center, AbSci, Absorption Systems, Abvitro, Academic Drug Discovery Consortium, Accent Therapeutics, Accenture, Accord, Acentrus Specialty, Acer Therapeutics, Acetylon Pharmaceuticals, Achillion Pharmaceuticals, AC Immune, Acino Pharma, Aclaris Therapeutics, ACMG Foundation for Genetic and Genomic Medicine, Acorda Therapeutics, Actavis (acquired by Watson), Actelion, ACT Genomics, Actinium Pharmaceuticals, Acura Pharmaceuticals, Adagene, Adamas Pharmaceuticals, Adamis Pharmaceuticals, Adaptimmune, Adaptive Biotechnologies, Adherium, Adimab, Adlai Nortye, ADMA Biologics, Adocia, AdoRx Therapeutics, Aduro BioTech, Advanced Cardiac Therapeutics, Advanz Pharma, Advaxis, Advent International, Advocate Health Care, Aegerion Pharmaceutical, Aeglea BioTherapeutics, Aelix Therapeutics, Aetion, Aetna, Aevi Genomic Medicine, Afaxys Pharmaceuticals, Affilogic, Affimed Therapeutics, Affinivax, AGC Asahi Glass, Age Labs, Agendia, Agensys, Agenus Bio, AgeX Therapeutics, Agios Pharmaceuticals, AgonOx, Aguettant, AIDS Foundation of Chicago, AIM ImmunoTech, AIMM Therapeutics, Aimmune Therapeutics, Akcea Therapeutics, Akebia Therapeutics, Akero Therapeutics, Akeso Biopharma, Akili Interactive Labs, Akorn, Albany Molecular Research, Albumedix, Alcon Laboratories, Alcyone Lifesciences, Alder Biopharmaceuticals, Aldeyra Therapeutics, Alector, Alexza Pharmaceuticals, AlivaMab Discovery Services, AliveGen, Alivio Therapeutics, ALK-Abello, Alkermes, Allele Biotechnology and Pharmaceuticals, Allergan, Allergan (name changed from Actavis), Alliance For Clinical Trials In Oncology, Alliance Global Group, Alliance Pharma, Allied-Bristol Life Sciences, Allied Minds, Alligator Bioscience, Allm, Allogene Therapeutics, Almac Discovery, Almac Group, Almirall, Alnylam Pharmaceuticals, Alphamab Biopharmaceuticals, Alpine Immune Sciences, ALS Association, Altavant Sciences, Alteogen, Altius Institute for Biomedical Sciences, Altor BioScience, Altos Group, Alveo Technologies, Alvogen, Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Alzheimer's Research UK, Alzheimers Research UK, AM-Pharma, Amal Therapeutics, Amazon Web Services, Ambys Medicines, American Association for Cancer Research, American Cancer Society, American College of Emergency Physicians, American College of Physicians Foundation, American College of Sports Medicine, American Diabetes Association, American Heart Association, American Liver Foundation, American Migraine Foundation, American Red Cross, American Society for Parenteral and Enteral Nutrition, American Society of Hematology, AmeriCares, Amerinet, Amgen, Amgros, Amneal Pharmaceuticals, AmorChem, Amorsa Therapeutics, Amoy Diagnostics, AMPATH Oncology Institute, Amphastar Pharmaceuticals, Amplyx Pharmaceuticals, AMRA Medical, Amunix, Amygdala Neurosciences, Amyris, AnaBios, Anaeropharma, Anavex Life Sciences, AnchorDx, Andromeda Biotech, Angelini Pharma, Angle, AnHeart Therapeutics, Anima Biotech, ANI Pharmaceuticals, Anji Pharma, Anokion, ANP Technologies, Antares Pharma, Antengene, Anthem, Anthera Pharmaceuticals, Anthos Therapeutics, Antigen Express, Apeiron Biologics, Apexigen, Apollo Therapeutics, Apotex, Apple, Applied BioMath, Applied DNA Sciences, Applied Molecular Transport, Apricus Biosciences, APRINOIA Therapeutics, Aptalis Pharmaceutical Technologies, Aptinyx, APT Therapeutics, Aqua Pharmaceuticals, Aquinox Pharmaceuticals, Arabio, Aralez Pharmaceuticals, Arcadia Consumer Healthcare, ArcherDX, ARCS Foundation, Arcturus Therapeutics, Arcus Biosciences, Arcutis Biotherapeutics, Ardelyx, Arena Pharmaceuticals, arGEN-X, Argentum Pharmaceuticals, argenx, Ariad Pharmaceuticals, Aridis Pharmaceuticals, Aris Global, Aristea Therapeutics, Arix Bioscience, Ark Biosciences, ArmaGen, Aronora, Arrakis Therapeutics, Array Biopharma, Arrowhead Pharmaceuticals, Arrow Pharmaceuticals, Arsia Therapeutics, Artes Biotechnology, Artisan Bio, Arvinas, Asahi Kasei, Asana Biosciences, Ascentage Pharma, Asclepia Outsourcing Solutions, Ascletis, ASKA Pharmaceuticals, Aslan Pharma, Aspen Global, Aspen Holding, Aspen Institute, Aspen Pharmacare Canada, Assembly Biosciences, Assertio Therapeutics, Astellas Pharma, Astellas Pharma Europe, Astellas Pharma US, Astellas Venture Management, Astex Pharmaceuticals, AstraZeneca, AstraZeneca HealthCare Foundation, Atara Biotherapeutics, Athenex, Athersys, Atnahs Pharma, Atomwise, Atreca, Audion Therapeutics, Aurobindo Pharma, Autifony Therapeutics, AUT Roche Diagnostics Laboratory, AUT University, Auxogyn, Avalanche Biotechnologies, Avalere Health, AvanSci Bio, AvantGen, Avara Pharmaceutical Services, AVEO Oncology, Avidity Biosciences, Avillion, Avitide, Avon Foundation, Awamedica, Axiom Worldwide, Axsome Therapeutics, Ayala Pharmaceuticals, Azitra, Back-A-Line, Bactevo, Baergic Bio, Bain Capital, Bank of America, Banner Alzheimer's Institute, Banting & Best Diabetes Centre (BBDC), Banyan Biomarkers, Basilea Pharmaceutica, Bausch & Lomb, Bausch Health Companies, Bavarian Nordic, Baxalta, Baxter International, Bayer, Bayer Animal Health, Bayer CropScience, Bayer Healthcare, Bayer Innovation, Bayer Schering Pharma, Bayer Technology Services, Bayer USA Foundation, Baylor College of Medicine, BDD Pharma, Beacon Discovery, Becton Dickinson, Bedford Laboratories, Beiersdorf, BeiGene, Beijing Strong Biotechnologies, Bellicum Pharmaceuticals, BenevolentAI, Ben Venue Laboratories, BE Pharmaceuticals, Berg, BerGenBio, Berkeley Lights, Berlin Chemie, Beryllium, Beth Israel Deaconess Medical Center, Bicycle Therapeutics, Bigfoot Biomedical, Bill and Melinda Gates Foundation, Bina Technologies, BIND Therapeutics, Bio-Techne, BioAmber, BioArctic Neuroscience, biOasis Technologies, BioAtla, BioCardia, Biocartis, Bioceros, BiocerOX Products, BioCision, Biocon, BIOCORP, bioCSL, BioCurate, BioDelivery Sciences, Biofourmis, Biogen, Bioharmony Therapeutics, Biohaven Pharmaceutical Holding, Biohealth Innovation, BioInvent, BioLamina, BiolineRX, Biologics, BioLum Sciences, Biomedical Advanced Research and Development Authority, BIOMEDX Group, BioMed X Innovation Center, bioMerieux, BioMotiv, Biomunex Pharmaceuticals, BiomX, Bioncotech Therapeutics, Bioniz Therapeutics, Bionomics, BioNTech, BioPharma Plasma, BioPorto, Bio Products Laboratory, BioQ Pharma, BioRap Technologies, BioRestorative Therapies, BioSerenity, BioSurfaces, Biotest, Biothera Pharmaceuticals, Biotoscana Farma, Bioventus, Bioverativ, Biovista, BioXcel, Blackford, Bleeding Disorders Foundation, BlinkBio, Bluebird Bio, Blue Mesa Health, Blueprint Medicines, BMG Pharmaceuticals, BMV Medica, Boehringer Ingelheim, Boehringer Ingelheim Vetmedica, Bone Therapeutics, Bonnie J. Addario Lung Cancer Foundation, Boston Biomedical, Boston Pharmaceuticals, Boston Scientific, Boston Strategics, Boston University School of Medicine, Box, BPL Medical Technologies, Brainomix, BrainStem Biometrics, Breast Cancer Research Foundation (BCRF), BridgeBio Pharma, Bridge Biotherapeutics, Brigham and Women's Hospital, BrightInsight, BRIM Biotechnology, Bristol-Myers Squibb, Bristol-Myers Squibb Foundation, Bristol-Myers Squibb Pakistan, Broad Institute, Butantan Institute, BWK, C2N Diagnostics, C4 Therapeutics, Cadence Pharmaceuticals, Cadent, Cadila Pharmaceuticals, Caladrius Biosciences, Calico, California Institute for Biomedical Research, California Institute for Quantitative Biosciences (QB3), California State University, Calithera Biosciences, Cambrex, Camena Bioscience, CAMP4 Therapeutics, Canadian Cancer Society, Canadian National Transplant Research Program, CANbridge Life Sciences, Cancer Genetics, Cancer Research Institute, Cancer Research Society, Cancer Research Technology, Cancer Research UK, Candel Therapeutics, Capricor Therapeutics, Cara Care, Cara Therapeutics, Cardiff University, Cardinal Health, Cardinal Partners, Cardiome Pharma, Cardiorentis, Cardurion Pharmaceuticals, Carepay, Caribou Biosciences, Carl Zeiss Meditec, Carmine Therapeutics, Carmot Therapeutics, Carna BioSciences, Casebia Therapeutics, CASI Pharmaceuticals, Casper Pharma, Catalan Institute of Nanotechnology (ICN), Catalent, Catalyst Biosciences, CDR-Life, Cedars-Sinai Medical Center, Celdara Medical, Celgene, Celimmune, Celladon, Celldex Therapeutics, Cellectis, CELLINK, CellSight Technologies, Celltech, Cell Therapy, Celltrion, Cellular Biomedicine, Cellular Dynamics International, Celmatix, Celsius Therapeutics, Cenix BioScience, Center for Connected Health, Center for Human Genetics and Laboratory Medicine, Center for Infectious Disease Research, Center for iPS Cells Research and Application, Centers for Disease Control and Prevention, Centers for Medicare and Medicaid Services, Centogene, Centre for Drug Design and Discovery, Centre for Drug Research and Development (CDRD), Centrexion, Cephea Valve Technologies, Cepheid, Cerecor, Ceres, Cerevance, Cerevel Therapeutics, Certara, Cerulean Pharma, Cerveau Technologies, Cevec Pharmaceuticals, Champions Oncology, Charles River Laboratories, Charleston Laboratories, Checkmate Pharmaceuticals, Checkpoint Therapeutics, Chembio Diagnostics, ChemDiv, Chemical Abstracts Service (CAS), Cheplapharm Arzneimittel, Chi-Med, Chiesi Farmaceutici, Children's Hospital Boston, Children's Hospital of Philadelphia, China Animal Husbandry Industry, China Medical System, China Southeast University, Chinese Academy of Sciences, Chinook Therapeutics, Chromocell, Chronos Therapeutics, Chugai Pharmaceutical, Chugai Pharma Marketing, Cilag AG, Cincinnati Children’s Hospital Medical Center, CinCor Pharma, Cipla, Circassia, Circle Pharma, Circuit Therapeutics, City of Hope, CiVi Biopharma, Clarient, ClearPath, Clementia Pharmaceuticals, Cleveland Clinic, Click Therapeutics, Clinigen, CliniWorks, Clinton Health Access Initiative, Cloud Pharmaceuticals, Clover Biopharmaceuticals, Clover Therapeutics, Clovis Oncology, CMC Biologics, Coala Life, Coalition for Epidemic Preparedness Innovations, Cobra Biologics, Cocrystal Pharma, Codexis, Cognition Kit, CogState, Coherus Biosciences, Cold Genesys, Cold Spring Harbor, Columbia University, Columbia University Medical Center, Compact Imaging, Complix, Compugen, Conatus Pharmaceuticals, Concerto HealthAI, Concordia Healthcare, Confo Therapeutics, Connexios, Contextual Genomics, Convelo Therapeutics, Cooper-Vemedia, Cooper Companies, Cordis, Corgenix Medical, Cornell University, Corning, CorTechs Labs, Cortexyme, Corvidia Therapeutics, Corvus Pharmaceuticals, COTA, Council for Economic Defense (Brazil), COUR Pharmaceutical, Courtagen Life Sciences, Covance, Covestro, Crescendo Biologics, CRISPR Therapeutics, CrowdMed, Crown Laboratories, Crucell, Crystal Bioscience, CSL, CSL Behring, CSPC Pharmaceutical Group, CStone Pharmaceuticals, CTI BioPharma, Cubist Pharmaceuticals, Cue Biopharma, Cumberland Pharmaceuticals, Curadev Pharma, CureVac, Curie-Cancer, CURx Pharmaceuticals, CVC Capital Partners, Cyclenium Pharma, Cyclica, Cyon Therapeutics, Cypralis, Cyrenaic Pharmaceuticals, Cystic Fibrosis Foundation, Cystic Fibrosis Foundation Therapeutics, Cytel, Cytokinetics, CytomX Therapeutics, Cytoo, CytoReason, Daiichi Sankyo, Dainippon Pharmaceutical, Dainippon Sumitomo Pharma, Dako, Daktari Diagnostics, Dana-Farber Cancer Institute, Dare Bioscience, DarwinHealth, David H. Koch Institute for Integrative Cancer Research, Da Volterra, DayTwo, DEARhealth, Debiopharm, Debiotech, deCODE Genetics, Deerfield Management, DelSiTech, Denali Therapeutics, Dendreon, Denovo Biopharma, Department of Defense, Department of Energy, Department of Health and Human Services, DepoMed, DePuy, Dermala, Dermavant Sciences, Dermira, Desma HC, Dewpoint Therapeutics, DexCom, DiamiR, Diamond Light Source, Diaprost, Diasend, DiCE Molecules, Dicerna Pharmaceuticals, dievini Hopp BioTech, Digital Therapeutics Alliance, DILIsym Services, Dimension Therapeutics, Diosynth, Diplomat, Disc Medicine, Discuva, Distributed Bio, DNAtrix, DNX Biopharmaceuticals, Domain Therapeutics, Dorizoe Lifesciences, Dr. Reddy's Laboratories, Dr. Susan Love Research Foundation, Dragonfly Therapeutics, Draper Laboratories, DRI Capital, Drugs for Neglected Diseases Initiative, Dual Therapeutics, Duchesnay, Duke-NUS Graduate Medical School Singapore, Duke Clinical Research Institute (DCRI), Duke University, Durect, Dyadic International, Dynavax Technologies, Dyno Therapeutics, Dystonia Medical Research Foundation, E-Scape Bio, Eagle Pharmaceuticals, EA Pharma, Easton Pharmaceuticals, EB Pharma, Ecole Polytechnique Federale de Lausanne, EDAP TMS, Eddingpharm, Edelris, Edison Pharmaceuticals, Editas Medicine, Edwards Lifesciences, eFFECTOR Therapeutics, Egalet, Egle Therapeutics, Eiger BioPharmaceuticals, EirGenix, Eisai, Eisai Inc, Elanco, Elasmogen, Eleven Biotherapeutics, Eli Lilly, Elixirgen, Ellume, Embark Biotech, Emcure Pharmaceuticals, EMD Serono, Emendo Biotherapeutics, Emergent BioSolutions, Emirates Diabetes Society, Emisphere, Emory University, Empatica, Emulate, Enable Injections, Enamine, Encore Dermatology, Encycle Therpaeutics, Endo International, Endo Pharmaceuticals, Energesis Pharmaceuticals, Engage Therapeutics, enGene, EnGeneIC, Enigma Biomedical, Enleofen Bio, Ensemble Therapeutics, Entasis Therapeutics, Entegra Laboratories, Enteris Biopharma, Enterome Bioscience, Enumeral Biomedical, EnvisionRx, Enzyre, Enzyvant Science, Eolas Therapeutics, EpiDestiny, Epigen Biosciences, Epilepsy Foundation (EF), Epirus Biopharmaceuticals, EpiThany, Epivax, Epizyme, EPS International, Erasmus University Medical Center, ERP Biomarker Qualification Consortium, ERS Genomics, Esperion Therapeutics, Esteve, Ethicon Endo-Surgery, ETH Zurich, Etubics, Eureka Therapeutics, European Commission, European Molecular Biology Laboratory, EUSA Pharma, Evaxion Biotech, Evogen, Evolve BioSystems, Evonik Industries, EvoRX Technologies, Evotec, Evox Therapeutics, Ewopharma, Exactis Innovation, Exact Sciences, Exagen Diagnostics, Excelera Network, Excelra, Exco InTouch, Exelixis, Exicure, Exonate, Exosome Diagnostics, ExScientia, Eyegate Pharmaceuticals, Eyevance, F-Star, F-Star Alpha, Facebook, Facit, Famy Care, Fate Therapeutics, Fauna Bio, Fedora Pharmaceuticals, Feldan Therapeutics, Ferozsons Laboratories, Ferring Pharmaceuticals, Fibrogen, Fimbrion Therapeutics, Finch Therapeutics, FitBit, Five Prime Therapeutics, Flamma, Flatiron Health, FLX Bio, FOB Synthesis, Foghorn Therapeutics, Fondazione Telethon, Fonterra, Food and Drug Administration (FDA), Forendo Pharma, Forest Pharmaceuticals, Forge Therapeutics, FORMA Therapeutics, Fortelinea Software Systems, Fortive, Fortress Biotech, Forty Seven, Forward Pharma, Foundation for the National Institutes of Health (FNIH), Foundation Medicine, Fox Chase Cancer Center, Francis Crick Institute, Fraunhofer Institute for Molecular Ecology (IME), Frazier Healthcare Ventures, Frederick National Laboratory For Cancer Research, Fred Hutchinson Cancer Research Center, French National Institute for Agricultural Research, Frequency Therapeutics, Fresenius Kabi Pharmaceuticals, Fresenius Medical Care, FSC Laboratories, FSC Pediatrics, Fujifilm, Fujifilm Diosynth Biotechnologies, Fujifilm Kyowa Kirin Biologics, Fujirebio Diagnostics, Fulcrum Therapeutics, Fulgent Pharma, Fundacion Medina, Fundacion Progreso y Salud, Fusion Genomics, G1 Therapeutics, Gaia, Galapagos, Galderma, Galecto, Galvani Bioelectronics, GamaMabs Pharma, GammaDelta Therapeutics, Gan & Lee, Garvan Institute of Medical Research, Gatehouse Bio, Gateway Hemophilia Association, GC Pharma, GE Healthcare, Geisinger Health System, Geisinger Medical Center, Gemphire, Gencia Biotech, Genea Biomedx, GeneCentric Therapeutics, GeneData, Genentech, Genestack, GeNeuro, Genexine, Genialis, Genmab, Genome and Company, GenomeDx, Genometry, Genomic Health, Genomics, genOway, Genpact, GenScript USA, Genzyme, Georgetown University, Georgia Institute of Technology, German Cancer Research Center, German Federal State Baden-Wurttemberg, German Government, Geron, Gilead Sciences, Glaxo Group, GlaxoSmithKline, GlaxoSmithKline Biologicals, Glenmark Pharmaceuticals, Global Blood Therapeutics, Global Coalition for Adaptive Research, Global Genomics Group, Global Health Innovative Technology Fund (GHIT), Global Lung Cancer Coalition, Global Stem Cell Technology, GlucoMe, Glycotope Biotechnology, Glycyx Pharmaceuticals, Glykos, Glympse Bio, GNA Biosolutions, GNS Healthcare, Godrej, Goethe University Frankfurt, Goldfinch Bio, Good Start Genetics, Google, Gossamer Bio, GO Therapeutics, Government of Canada, Government of France, Government of Netherlands, Gowan Crop Protection, Gradalis, Grady Health System, Grail, Grameen Health, Greenlight Biosciences, Greenr U, Gritstone Oncology, GRU Cancer Center, Grunenthal, Grupo Ferrer, GRYT Health, GSK Consumer Healthcare, GT Biopharma, Guangzhou Institute of Respiratory Disease, Guardant Health, Gubra, H3 Biomedicine, Hackensack Meridian Health, Halozyme Therapeutics, Hamilton Thorne, Hanmi Pharmaceutical, Haplogen, Happify Health, HAPPYneuron, Harbour Biomed, Harm Reduction Therapeutics, Harpoon Therapeutics, Harvard Medical School, Harvard Pilgrim Health Care, Harvard Stem Cell Institute, Harvard University, Hatchtech, Health2Sync, HealthCore, Health Ministry (Italy), HealthPrize Technologies, Healx, Heart Rhythm Society, Hebrew University of Jerusalem, Helsinn Healthcare, Hemophilia Foundation of Southern California, HemoShear, Hennepin County Medical Center, Hetero Labs, Hi-Tech Pharmacal, HiFiBio, Highmark Blue Shield, HighRes Biosolutions, Hikma Pharmaceuticals, Histogen, Hitachi Chemical, HitGen, Hoffmann La Roche, Holobiome, Homology Medicines, Hookipa Pharma, Hope Medicine, Horizon Discovery, Horizon Pharma plc, Hospira, HP, Hsiri Therapeutics, HTG Molecular Diagnostics, Humabs BioMed, Humana, Human Longevity, Hummingbird Bioscience, HUYA Bioscience, Hydra Biosciences, Hypera Pharma, I-mab, IBM, IBM Watson Health, Icagen, Icahn School of Medicine at Mount Sinai, Ichor Medical Systems, Icon, Iconic Therapeutics, ICU Medical, IDEAYA Biosciences, Idera Pharmaceuticals, Idorsia, Ieso Digital Health, IFM Therapeutics, Igenica, iGenomix, IGNITE Immunotherapy, Ignyta, Iktos, Illumina, ILTOO Pharma, ImaBiotech, Imaflex, ImaginAb, ImClone Systems, Imcyse, Immatics Biotechnologies, Immugenyx, Immune Biosolutions, Immune Deficiency Foundation, Immune Design, Immuneering, Immune Pharmaceuticals, ImmuNext, Immunic, ImmunoBrain Checkpoint, Immunocore, ImmunoGen, Immunomedics, Immunomic, ImmunoPrecise Antibodies, ImmunoQure, Immunovaccine, Immutep, Impax Laboratories, Imperial College London, Imperial Innovations, IMS Health, Inception 5, Inception Sciences, Incyte, Indiana Biosciences Research Institute, Indiana University, Industrial Technology Research Institute, Infectious Disease Research Institute (IDRI), Infinity Pharmaceuticals, Inflammasome Therapeutics, Ingenza, Innate Pharma, Innerworkings, Innovate UK, Innovation Health, Innovation Network Corporation, Innovative Genomics Initiative (IGI), Innovative Medicines Initiative (IMI), Innovative Targeting Solutions, Innovent Biologics, Inotrem, Inovalon, iNova Pharmaceuticals, Inovio Pharmaceuticals, Inserm, Insilico, Insilico Medicine, Insitro, Insmed Inc, InSphero, Inspirion Delivery Sciences, Institut Curie, Institute for Research in Immunology and Cancer – Commercialization of Research, Institute for Systems Biology, Institute of Cancer Research, Institut Gustave Roussy, Institut Pasteur, Insulet, InsuLine Medical, Intarcia Therapeutics, Intas Biopharmaceuticals, Intec, Integral Molecular, Intel, Intellia Therapeutics, Intellikine, Intellimedix, Intellipharmaceutics, Intensity Therapeutics, InteRNA Technologies, International Association for the Study of Lung Cancer, International Diabetes Federation (IDF), International Myeloma Foundation, International Partnership for Microbicides, International Process Plants, International Vaccine Institute (IVI), Interprotein, Intrexon, Invenra, Inventiva, InVivoScribe, INVO Bioscience, InxMed, IO Biotech, Ionis Pharmaceuticals, IONTAS, Iovance Biotherapeutics, iPharma, Ipsen, IQVIA, IRBM, Iroko Pharmaceuticals, Ironwood Pharmaceuticals, Isarna Therapeutics, Italian Government, iTeos Therapeutics, ITM Isotopen Technologien, IXICO, Izana Bioscience, Jacobio Pharmaceuticals, Janssen-Cilag, Janssen Biotech, Janssen Human Microbiome Institute, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Janssen Sciences, Janssen Therapeutics, Janus Pharmaceuticals, Japan Agency for Medical Research and Development, Japan Tobacco, Jasper Therapeutics, JCR Pharmaceuticals, JDP Therapeutics, JenKem Technology, Jenner Institute, JHL Biotech, Jiangsu Chia Tai Tianqing Pharmaceutical, Jnana Therapeutics, Johns Hopkins Kimmel Cancer Center, Johns Hopkins Medicine (JHM), Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Consumer Companies, Johnson & Johnson Innovation, Johnson & Johnson Vision, Joslin Diabetes Center, Jounce Therapeutics, Jubilant Biosys, Jubilant Life Sciences, Juno Therapeutics, Junshi Biosciences, Juvenile Diabetes Research Foundation, Juventas Therapeutics, Juvise Pharmaceuticals, Kadimastem, Kadmon Pharmaceuticals, KAHR Medical, Kaken Pharmaceutical, Kaleido Biosciences, Kallyope, KalVista Pharmaceuticals, Kamada, Kanyos, Karl Storz, Karolinska Institute, Karyopharm Therapeutics, KBI BioPharma, Keio Gijuku University, KeyBioScience, Kiadis Pharma, KineMed, Kineta, Kings College London, Kiniksa Pharmaceuticals, Kissei Pharmaceutical, Kit Check, Kite Pharma, Klaria, Kneat, Knight Therapeutics, Kolon Life Science, Koneksa Health, Korea Health Industry Development Institute, Kowa Pharmaceuticals America, Kramer Laboratories, Kronos, KTH Royal Institute of Technology, Kura Oncology, Kymab, Kymera Therapeutics, Kyn Therapeutics, Kyorin Pharmaceutical, Kyoto University, Kyowa Hakko Kirin, Kyverna Therapeutics, L'Oreal, LabCentral, Labcyte, LABORATORIOS SAVAL, Laekna, Lannett, Lava Therapeutics, Lazada Group, Lazarex Cancer Foundation, Lead Discovery Center, Lead Pharma, Leap Therapeutics, Lee Moffitt Cancer Center, Legend Biotech, LegoChem Biosciences, Leica Biosystems, Leicester University, Leiden University, Leon-nanodrugs, LEO Pharma, Les Laboratoires Servier, Leukemia & Lymphoma Society, Lexicon Pharmaceuticals, LFB Biotechnologies, LFB Group, Lieber Institute, LifeArc, LifeMax Laboratories, Ligand Pharmaceuticals, Light Chain Bioscience, Lilly Endowment, Lincoln Equities Group, Linnaeus Therapeutics, Lipigon Pharmaceuticals, Litesprite, Litha Pharma, Liverpool School of Tropical Medicine, Living Proof, Livongo Health, LLamasoft, Locemia Solutions, Locus Biosciences, Lodo Therapeutics, LogicBio Therapeutics, Lonza, Loxo Oncology, LTS Lohmann Therapie-Systeme, Lubris BioPharma, Luc Therapeutics, Luminex, Luminostics, Lumora, Lumos Pharma, Lundbeck, Lund University, Lung Cancer Research Foundation, Lupin, Lupin Limited, Lupin Pharmaceuticals, Lupus Foundation of America (LFA), Lupus Research Alliance, Lupus Therapeutics, Luxna Biotech, Luye Pharma Group, Lycera, Lyfebulb, Lyndra Therapeutics, Lyra Health, Lysando, Lyvgen Biopharma, M2Gen, MAB Discovery, Mabion, MabVax Therapeutics, Macrogenics, Magellan Health Services, Magenta Therapeutics, Mallinckrodt Pharmaceuticals, Mammoth Biosciences, MannKind Biopharmaceuticals, Mapi Pharma, Mapp Biopharmaceutical, Marathon Pharmaceuticals, Marian University, Massachusetts General Hospital, Massachusetts Institute of Technology, MassBio, MaSTherCell, Maverick Therapeutics, Max-Planck, Max Foundation, Maxor National Pharmacy, Mayne Pharma, Mayo Clinic, MC10, McCall MacBain Foundation, McGill University, McNeil Consumer Pharmaceuticals, MD Anderson Cancer Center, MDG Health Alliance, MDxHealth, Mectizan Donation Program, Meda, Medac, MedGenesis Therapeutix, Medgenics, MEDIAN Technologies, Medibio, Medicago, Medical Developments International, Medical Prognosis Institute, Medical Research Council, Medical Research Foundation, Medical University of South Carolina, Medicines360, Medicines Patent Pool Foundation, Medicure, Medidata Solutions, Medimetriks, MedImmune, Medipal Holdings, MediSafe, Medivation, Medivir, Medtronic, Meiji Seika, Meiogenix, MEI Pharma, MeiraGTx, Melinta Therapeutics, MEME, Memorial Sloan Kettering Cancer Center, Menarini, Menarini Asia-Pacific, Mentor, Merck and Co, Merck Animal Health, Merck Company Foundation, Merck KGaA, Merck Serono, Merck Sharpe & Dohme, Mereo BioPharma, Merial, Merrimack Pharmaceuticals, Mersana Therapeutics, Merus Labs International, Merz, Metabolon, Metacrine, Metastatic Breast Cancer Network, MetaSysX, METAvivor, Michael J Fox Foundation, Microbiotica, Microchips Biotech, MicroHealth, Microsoft, Millendo Therapeutics, Millennium, Milner Therapeutics Institute and Consortium, Mimetogen Pharmaceuticals, MiNA Therapeutics, MiNDERA, MindImmune Therapeutics, Mindstrong Health, Minerva Neurosciences, Ministry of Health, Labor and Welfare, Ministry of Health and Prevention, Miragen Therapeutics, Mirati Therapeutics, Mirum Pharmaceuticals, MiRXES, Mission Pharmacal, Mission Therapeutics, MiTest Health, Mitsubishi Tanabe Pharma, Moberg Pharma, Moderna Therapeutics, Modern Biosciences, Moebius Medical, Molecular Devices, MolecularMD, Molecular Partners, Molecular Stethoscope, Molecular Templates, Mologen, Molplex Pharmaceuticals, Momenta Pharmaceuticals, Monash University, Monsanto, Morphic Therapeutic, MorphoSys, Mount Sinai Health System, Mount Sinai Medical Center, MSD, Multiple Myeloma Research Foundation, Mundipharma, My Brother’s Keeper, Myeloma UK, Mylan Laboratories, Mylan Pharmaceuticals, Mymetics, MyoKardia, Myovant Sciences, Myriad Genetics, Myriad RBM, Nabriva Therapeutics, Nanoform, nanoPET Pharma, NanoString Technologies, Nanotherapeutics, NantBioScience, NantCell, NantKwest, NantWorks, NapaJen Pharma, Narayana Nethralaya Foundation, National Academy of Sciences, National Cancer Center, National Cancer Institute, National Center for Cardiovascular Diseases, National Comprehensive Cancer Network (NCCN), National Healthcare Services (NHS), National Health Service, National Institute for Health Research (NIHR), National Institute for Public Health and the Environment, National Institute of Allergy and Infectious Diseases, National Institute of Infectious Diseases, National Institute of Molecular Genetics, National Institute of Neurological Disorders and Stroke, National Institute of Standards and Technology, National Institute on Drug Abuse (NIDA), National Institutes of Health, National Newspaper Publishers Association, National Psoriasis Foundation, National Research Council Canada, National Surgical Adjuvant Breast and Bowel Project, Natrix Separations, Ncardia, Nektar Therapeutics, Nemaura Pharma, Neogenomics, NeoImmuneTech, NeoMed, Neon Therapeutics, Neos Therapeutics, Nerviano Medical Sciences, Nestle, NETRIS Pharma, NetVation DL Medicine, Neumentum, Neurocrine Biosciences, NeuroCycle Therapeutics, NeuroMetrix, Neuronetics, Neuronetrix, Neuropore Therapies, NeuroSigma, NeuroTracker, NeuroVision Imaging, NeuTec Pharma, New Brunswick Health Research Foundation, New York Genome Center (NYGC), NextCure, Nextera, Nference, NGM Biopharmaceuticals, Nicox, Nikkiso, Nimble Therapeutics, Nimbus Therapeutics, Ningbo NewBay Medical Technology, Ningbo Tai Kang Medical Technology, Nitto Denko, Nodality, Nogra Pharma, Noile-Immune Biotech, Noom, Nordic Bioscience, Norgine, Northern Biologics, Northern California Institute for Research and Education, North Georgia Healthcare, Northwestern University, NovAliX, Novartis, Novartis Consumer Health, Novartis Institute for Tropical Diseases, Noven Pharmaceuticals, NovImmune, Novocure, Novoheart, Novo Nordisk, Novozymes, Novozymes Biopharma, Noxxon Pharma, Nrgene, NuBiyota, Nuevolution, Numab, NuMedii, Numerate, Nurix, Nutritional Growth Solutions, Nuvelution Pharma, Nuviant Medical, NuView Life Sciences, NuvoAir, NXT Biomedical, OARO, OBI Pharma, Obsidian Therapeutics, Ochsner Health System, Octapharma, Ocular Therapeutix, Oculis, Ogeda, Ohio State University, OKKO Health, Oklahoma Health Care Authority, Oklahoma Medical Research Foundation, OliPass, Olympus Biotech, Omada Health, Onco360, Oncodesign, Oncoheroes Biosciences, OncoImmune, Oncologie, Oncology Venture, Oncolytics Biotech, OncoMed Pharmaceuticals, OncoSec Medical, One Drop, oNKo-innate, Ono Pharmaceutical, Ontario Institute for Cancer Research, Open Monoclonal Technology, OpGen, Ophirex, Ophthotech, Opiant Pharmaceuticals, OPKO Health, Optibrium, Optum, Oracle Health Sciences, OraSure Technologies, Orca Pharmaceuticals, Orchard Therapeutics, Orexigen Therapeutics, Organogenesis, ORIC Pharmaceuticals, OrigiMed, Orion, Orionis Biosciences, Oryzon, Osaka University, OSE Immunotherapeutics, OSI Pharmaceuticals, Oslo University Hospital, Ossianix, Otonomy, Otsuka, Otsuka America Pharmaceutical, Outpost Medicine, Ovensa, Ovid Therapeutics, Owlstone Medical, Oxford Biodynamics, Oxford BioMedica, Oxford BioTherapeutics, Oxygen Biotherapeutics, Padlock Therapeutics, Pain Therapeutics, Palantir, Palobiofarma, Panasonic Healthcare, panCELLa, Pandion Therapeutics, PanTheryx, Parexel, Parkinson's Institute and Clinical Center, Partner Therapeutics, Parvus Therapeutics, Patheon, PatientFi, PatientsLikeMe, PCI Biotech, PDL BioPharma, PDS Biotechnology, PEAR Therapeutics, PegBio, Peking University, Pendopharm, PeptiDream, Peregrine Pharmaceuticals, Perlara, Pernix Therapeutics, Perrigo, Personal Genome Diagnostics, Personalis, Personalized Medicine Initiative (PMI), PersonalizeDx, Perthera, PetaGene, Petra Pharma, Pfenex, Pfizer, Pfizer Canada, Pfizer Consumer Health, Pfizer Japan, Phadia, Phanes Therapeutics, PharmAbcine, Pharmacyclics, PharmaEngine, PharmaIN, PharmaMar, Pharmaron, Pharmaxis, Pharming Group, PhaseBio Pharmaceuticals, Phathom Pharmaceuticals, Phenex, Philips, Phillips-Medisize, Philogen, Phlexglobal, Phoenix Molecular Designs, PhoreMost, Phylogica, PicnicHealth, Pieris, Pierre Fabre, Ping An Ventures, Pionyr Immunotherapeutics, Piramal, Planet Wheeler Foundation, Pliant Therapeutics, Police Athletic League of New York City, Polpharma, Portal Instruments, Portola Pharmaceuticals, Poseida Therapeutics, Potenza Therapeutics, Poxel, Pozen, PPD, Pragma Pharmaceuticals, Prana Biotechnology, Prasco Laboratories, Prayog Labs, Precigen, Precision Biologics, Precision BioSciences, Preferred Care, Premier Inc, Presage Biosciences, Prevencio, Prime Therapeutics, Princess Maxima Center for Pediatric Oncology, Principia Biopharma, Probi, Probiodrug, ProBioGen, Procella Therapeutics, Process Systems Enterprise, Procter & Gamble, Progenics Pharmaceuticals, Project Inform, Prokaryotics, Prometheus Laboratories, Propeller Health, Prophase Labs, Prosetta Biosciences, Prosonix, Protagen, Protagonist Therapeutics, Protalix BioTherapeutics, Protectimmun, ProteinQure, ProteoNic, Proteostasis Therapeutics, Proteros biostructures, Prothena Biosciences, ProThera, Provectus Biopharmaceuticals, Provention Bio, ProvideGx, Proximagen Group, Proximagen Neuroscience, PsiOxus Therapeutics, pSivida, Pulmatrix, Pulmonary Fibrosis Foundation (PFF), Puma Biotechnology, Punjab Province, Purdue Pharma, Purdue University, PureTech Health, Puridify, PvP Biologics, Pyramid Biosciences, Q-State Biosciences, Q32 Bio, QED Therapeutics, Qiagen, Qualcomm, Qualcomm Life, Qualcomm Ventures, Quantum Materials, Quartet Medicine, Quebec Urological Association Foundation, Queen Mary University of London, Queensland Institute of Medical Research (QIMR), Queensland University of Technology, Quintiles, Quintiles IMS Holdings, QurAlis, Qura Therapeutics, R-Biopharm, R-Pharm, Radius Health, Rafael Pharmaceuticals, Rainbow Medical, Raisio, Rakuten Medical, Ramot at Tel Aviv University, Ranbaxy Laboratories, Rani Therapeutics, RareGen, Recordati, ReCor Medical, Recursion, RedHill Biopharma, Redwood Bioscience, Redx Pharma, RefleXion Medical, ReForm Biologics, Regenacy Pharmaceuticals, Regen BioPharma, Regeneron Genetics Center, Regeneron Pharmaceuticals, Regents of the University of Michigan, Regenxbio, REGiMMUNE, Regulus Therapeutics, RelianceHMO, Relief Therapeutics, Relypsa, Remedy Pharmaceuticals, reMYND

For a full list please contact us on orders@currentpartnering.com

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.